Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €65.00 ($75.58) price target by investment analysts at Deutsche Bank in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the stock. Deutsche Bank’s price objective points to a potential upside of 37.77% from the stock’s previous close.

A number of other equities research analysts have also weighed in on FRE. UBS Group set a €46.00 ($53.49) price objective on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Monday. Credit Suisse Group set a €45.00 ($52.33) price objective on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Friday, December 14th. Cfra set a €45.00 ($52.33) price objective on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Friday, December 7th. DZ Bank reiterated a “neutral” rating on shares of Fresenius SE & Co KGaA in a report on Thursday, October 18th. Finally, Sanford C. Bernstein set a €76.50 ($88.95) price objective on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Friday, December 7th. Nine research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of €61.34 ($71.32).

Shares of FRE opened at €47.18 ($54.86) on Tuesday. Fresenius SE & Co KGaA has a 1-year low of €60.16 ($69.95) and a 1-year high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

See Also: Float

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.